中新网天津2月6日电 (记者 王君妍)记者6日从天津港保税区获悉，由中国科学院天津工业生物技术研究 所(以下简称天津工生所)牵头承担的国家重点研发计划"合成生物学"重点专项——"基于虚拟细胞技术的 合成基因回路与底盘细胞协同设计"项目启动会日前在天津举行。 项目启动会上，项目及课题负责人围绕项目背景、总体设计、研究内容、技术路线及最新进展等方面进 行了系统汇报。咨询专家组充分肯定了项目的前沿定位和交叉融合特色，并就虚拟细胞模型构建策略、 人工智能与机理模型融合路径、面向细胞工厂与细胞治疗应用的关键技术突破等提出了建设性意见。 天津工生所所长向华表示，该项目的实施，将有助于提升我国在生物设计底层工具与核心模型的创新能 力，为抢占下一代生物制造制高点提供有力支撑。 天津港保税区相关负责人表示，作为天津大力发展合成生物创新策源、推动生物制造产业高质量发展的 重要承载地，天津港保税区全力打造"生物制造先导区"，并已在区域内构建起以天津工生所、国家合成 生物技术创新中心等平台为核心的研发策源体系，涌现出二氧化碳人工合成淀粉、DNA合成仪、健康 糖等一批标志性项目。(完) 据介绍，该项目聚焦合成生物学与人工智能前沿交叉领 ...

Core Insights - The life sciences instrument sector is experiencing significant capital inflow and technological innovation in 2025, with a notable trend towards domestic substitution [1][2] - The financing activity in the first half of 2025 has surpassed that of the same period in 2024, with a total of approximately 1.5 billion yuan raised across 13 financing events [2] Financing Overview - In the first half of 2025, 13 financing events were completed, totaling around 1.5 billion yuan, with a balanced distribution across various financing rounds: 4 in A round, 4 in B round, 3 in C round, and 2 in angel round [2] - Key financing events include: - Kunpeng Gene: over 100 million yuan in B round [2] - Yinsais: several hundred million yuan in C round [2] - Zhenmai Bio: 280 million yuan in C+ round, the highest amount in the first half [3][2] Sector Analysis - Sequencing and synthetic biology are leading the investment landscape, with sequencing-related companies accounting for over 30% of the financing events [3] - The market for sequencing instruments is expected to maintain a compound annual growth rate of over 20% due to increasing demand for precision medicine and single-cell sequencing [3] Synthetic Biology Financing - Synthetic biology has emerged as a hot investment area since 2024, continuing into 2025, with significant financing amounts [4] - Companies like Yinsais and Lingzhi Technology are focusing on nucleic acid synthesis and DNA synthesis, respectively, aligning with global trends in mRNA technology [4] AI and Advanced Instrumentation - Companies are integrating AI with high-end instrumentation, exemplified by Tianlu Technology's intelligent experimental design tools and Chaowei Jing's multi-photon microscope [5] - This trend indicates a shift towards interdisciplinary innovation, enhancing the competitiveness of domestic instruments [5] Domestic Instrumentation Landscape - Lid Health's substantial angel round financing has drawn attention, positioning the company as a comprehensive supplier of high-end life science instruments [6] - The company aims to consolidate the market by acquiring smaller players, drawing parallels with international leaders like Thermo Fisher [6] Policy and Market Dynamics - The rapid development of domestic life science instruments is driven by supportive policies and growing market demand, particularly in biomedicine and CGT sectors [7] - Despite active financing, domestic manufacturers face challenges such as reliance on imported core components and the need for brand recognition [7] Future Outlook - The life sciences instrument sector is expected to see a shift from broad investment strategies to a more focused approach, favoring companies with high technological barriers and significant domestic substitution potential [8] - The industry is anticipated to produce several "hidden champions" in niche areas within the next 3-5 years, moving towards the high end of the global value chain [8]

【SynBioCon】 获 悉， 4月28日，主题为"技术造物 创引未来"的天津港保税区生物制造产业新闻发 布会举行。会上，天津港保税区发布了 《天津港保税区推动生物制造产业高质量发展行动方案》 （以 下简称《行动方案》）和 《天津港保税区关于支持生物制造产业高质量发展的若干政策》 （以下简 称"生物制造十条"）。 近些年，生物制造作为全新的"造物"技术，成为全球竞相布局的科技战略高地。今年政府工作报告中 提到，因地制宜发展新质生产力，培育生物制造、量子科技、具身智能、6G等未来产业。我市去年已 印发《天津市加快合成生物创新策源推动生物制造产业高质量发展实施方案》，天津港保税区按照全市 工作部署正全力打造生物制造先导区。此次发布会展现了天津港保税区生物制造产业在创新策源、成果 产业化、空间布局、人才支撑、标志性项目等方面的先发优势及推动生物制造创新成果产业化应用实 践，促进新产业、新模式、新动能加快 落地。 01 政策上新 全力打造百亿级产业集群 记者从会上获悉，《行动方案》以推动生物制造创新成果产业化应用实践为主线，因地制宜构建符合新 质生产力发展的新型生产关系，重点聚焦创新策源地、孵化转化高地和创新生态三 ...